Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7380387 | 0.83 | TRIM24 (0.50) | HDAC1 | |
| SCHEMBL3290030 | 0.83 | PAM (0.44) | PAMALDH1A1CYP2A6HTTMAPT | |
| SCHEMBL1822585 | 0.81 | PAM (0.61) | PAMALDH1A1CYP2A6MAPTRECQL | |
| SCHEMBL3923075 | 0.78 | PAM (0.70) | PAMALDH1A1HTTMAPTRECQL | |
| SCHEMBL3087230 | 0.78 | JUN (0.45) | ALDH1A1CYP2A6CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15157265 | 0.78 | CYP2A6 (0.48) | ALDH1A1CYP2A6HTTMAPTLMNA | |
| SCHEMBL2676618 | 0.78 | HSD11B1 (0.45) | ALDH1A1MAPTLMNACYP1A2CYP2C9 | |
| SCHEMBL3161596 | 0.78 | SMN1; SMN2 (0.46) | MAPTLMNASMN1; SMN2NPSR1 | |
| SCHEMBL5329189 | 0.78 | ALDH1A1 (0.41) | PAMALDH1A1CYP2A6HTTMAPT | |
| SCHEMBL5680262 | 0.78 | PAM (0.70) | PAMALDH1A1HTTMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-9884860-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2018-02-06 | — | — | US | claimed |
| EP-2809669-B1 | FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-02-01 | — | — | EP | claimed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-06-09 | — | — | US | claimed |
| US-9284333-B2 | Fused pyrroledicarboxamides and their use as pharmaceuticals | SANOFI (FR) | 2016-03-15 | — | — | US | claimed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2907804-A1 | Novel 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics | Galderma Research & Development (FR) | 2015-08-19 | — | — | EP | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-8993596-B2 | 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-03-31 | — | — | US | claimed |
| EP-1659120-A1 | 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GlaxoSmithKline S.p.A. (IT) | 2006-05-24 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-1567507-A1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | claimed |
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-09-16 | — | — | US | claimed |
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | claimed |
| WO-2004050642-A1 | 1, 2, 3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| US-20040102492-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | claimed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | claimed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | claimed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | HRH4, HRH2, HRH3 | PAM 1132/4885ALDH1A1 3625/4885CYP2A6 3255/4885 |
| US-20040102492-A1 | Cytokine inhibitors | IL1A, IL1B, IL1RN | PAM 4488/4885ALDH1A1 272/4885CYP2A6 609/4885 |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | PAM 1248/4885ALDH1A1 752/4885CYP2A6 626/4885 |
| US-20160159793-A1 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals | KCNA1, KCNE1, KCNH1 | PAM 1688/4885ALDH1A1 716/4885CYP2A6 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.